Inclusion Criteria:

- Patient is of a legally consenting age as defined by local regulations.

- Patient is, in the investigator(s) opinion willing and able to comply with the
protocol requirements.

- Patient has given voluntary written informed consent before performance of any
study-related procedure not part of normal medical care, with the understanding that
consent may be withdrawn by the patient at any time without prejudice to their future
medical care.

- Female patient is either post-menopausal or surgically sterilized or willing to use
an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine
device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
duration of the study.

- Male patient agrees to use an acceptable method for contraception (i.e., condom or
abstinence) for the duration of the study.

- Patient was previously diagnosed with multiple myeloma based on standard criteria.

- Patient is relapsed or refractory after one or two lines of treatment including
high-dose chemotherapy with stem cell support, conventional poli-chemotherapy,
thalidomide- and melphalan-based regimens.

- Patient has measurable disease, defined as follows: any quantifiable serum monoclonal
protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein
and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain
excretion of >200 mg/24 hours.

- Patient has a Karnofsky performance status ≥60%.

- Patient has a life-expectancy >3 months.

- Patient has the following laboratory values within 14 days before Baseline (day 1 of
the Cycle 1, before study drug administration):

- Platelet count ≥75 x 109/L without transfusion support within 7 days before the test.

- Absolute neutrophil count (ANC) ≥ 0.75 x 109/L without the use of growth factors.

- Corrected serum calcium ≤14 mg/dL (3.5 mmol/L).

- Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN).

- Alanine transaminase (AST): ≤ 2.5 x the ULN.

- Total bilirubin: ≤ 1.5 x the ULN.

- Calculated or measured creatinine clearance: ≥20 mL/minute.

Exclusion Criteria:

- Patient has an absolute neutrophil count <0.75 × 109/L within 14 days before enrollment.

- Patient has a calculated or measured creatinine clearance <20 mL/minute within 14
days before enrollment.

- Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment.

- Patient has known hypersensitivity to bortezomib, boron, mannitol or thalidomide.